[1] 中华医学会感染病学分会, GRADE 中国中心. 中国乙型肝炎病毒母婴传播防治指南(2019 年版). 中华传染病杂志, 2019,37:388-396.
[2] 周乙华, 李彤, 庄辉. 对“中国乙型肝炎病毒母婴传播防治指南(2019 年版)”的商榷. 肝脏,2020,25:2-4.
[3] 刘锦锋, 陈天艳, 陈耀龙, 等. 对《对<中国乙型肝炎病毒母婴传播防治指南(2019 年版)>商榷》 一文的回复. 肝脏,2020,25:4-6.
[4] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol, 2017, 67:370-398.
[5] Lee JS, Mullaney S, Bronson R, et al. Transplacental antir-etroviral therapy with 9- (2- phosphonylmethoxyethyl) adenine is embryotoxic in transgenic mice. J Acquir Im-mune Defic Syndr, 1991, 4:833-838.
[6] Wong GL, Seto WK, Wong VW, et al. Review article: long-term safety of oral anti-viral treatment for chronic hep-atitis B. Aliment Pharmacol Ther, 2018, 47:730-737.
[7] Gu Y, Ru T, Zhou YH, et al. Adefovir as a possible terato-gen: Evidence from paternal exposure. Dig Liver Dis,2014, 46:1134-1135.
[8] Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 2018, 67: 1560-1599.
[9] Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Preg-nancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology, 2005,65:802-806.
[10] Lu E, Wang BW, Guimond C, et al. Disease- modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology, 2012, 79:1130-1135. |
